CLAIMS

1. A polypeptide, a composition comprising the polypeptide, or a composition comprising a nucleic acid comprising a nucleotide sequence that encodes the polypeptide, wherein said polypeptide comprises or consists of at least four immunoglobulin single variable domains (ISVDs), wherein each of said ISVDs comprises three complementarity determining regions (CDR1 to CDR3, respectively), optionally linked via one or more peptidic linkers; and wherein:

   a. a first ISVD and a second ISVD, each specifically binds to OX40L and each comprises

      i. a CDR1 comprising the amino acid sequence of SEQ ID NO: 7 or has 2 or 1 amino acid difference(s) with SEQ ID NO: 7;

      ii. a CDR2 comprising the amino acid sequence of SEQ ID NO: 10 or has 2 or 1 amino acid difference(s) with SEQ ID NO: 10; and

      iii. a CDR3 comprising the amino acid sequence of SEQ ID NO: 13 or has 2 or 1 amino acid difference(s) with SEQ ID NO: 13; and

   b. a third ISVD and a fourth ISVD, each specifically binds to TNF-α and each comprises

      iv. a CDR1 comprising the amino acid sequence of SEQ ID NO: 8 or has 2 or 1 amino acid difference(s) with SEQ ID NO: 8;

      v. a CDR2 comprising the amino acid sequence of SEQ ID NO: 11 or has 2 or 1 amino acid difference(s) with SEQ ID NO: 11; and

      vi. a CDR3 comprising the amino acid sequence of SEQ ID NO: 14 or has 2 or 1 amino acid difference(s) with SEQ ID NO: 14.

2. The polypeptide or composition according to claim 1, wherein:

a. said first ISVD and said second ISVD each comprise a CDR1 comprising the amino acid sequence of SEQ ID NO: 7, a CDR2 comprising the amino acid sequence of SEQ ID NO: 10 and a CDR3 comprising the amino acid sequence of SEQ ID NO: 13; and

b. said third ISVD and said fourth ISVD each comprise a CDR1 comprising the amino acid sequence of SEQ ID NO: 8, a CDR2 comprising the amino acid sequence of SEQ ID NO: 11 and a CDR3 comprising the amino acid sequence of SEQ ID NO: 14.

3. The polypeptide or composition according to any of claims 1 or 2, wherein:

a. the amino acid sequence of said first ISVD comprises a sequence identity of more than 90% with SEQ ID NO: 2;

b. the amino acid sequence of said second ISVD comprises a sequence identity of more than 90% with SEQ ID NO: 3;

c. the amino acid sequence of said third ISVD comprises a sequence identity of more than 90% identity with SEQ ID NO: 4; and

d. the amino acid sequence of said fourth ISVD comprises a sequence identity of more than 90% identity with SEQ ID NO: 6.

4. The polypeptide or composition according to any of claims 1 to 3, wherein:

a. said first ISVD comprises the amino acid sequence of SEQ ID NO: 2;

b. said second ISVD comprises the amino acid sequence of SEQ ID NO: 3;

c. said third ISVD comprises the amino acid sequence of SEQ ID NO: 4; and

d. said fourth ISVD comprises the amino acid sequence of SEQ ID NO: 6.

5. The polypeptide or composition according to any of claims 1 to 4, wherein said polypeptide further comprises one or more other groups, residues, moieties or binding units, optionally linked via one or more peptidic linkers, in which said

one or more other groups, residues, moieties or binding units provide the polypeptide with increased half-life, compared to the corresponding polypeptide without said one or more other groups, residues, moieties or binding units.

6. The polypeptide or composition according to any one of claims 4 or 5, in which said one or more other groups, residues, moieties or binding units that provide the polypeptide with increased half-life is chosen from the group consisting of binding units that can bind to serum albumin (such as human serum albumin) or a serum immunoglobulin (such as IgG).

7. The polypeptide or composition according to claim 6, in which said binding unit that provides the polypeptide with increased half-life is an ISVD that can bind to human serum albumin.

8. The polypeptide or composition according to claim 7, wherein the ISVD binding to human serum albumin comprises

   i. a CDR1 comprising the amino acid sequence of SEQ ID NO: 9 or has 2 or 1 amino acid difference(s) with SEQ ID NO: 9;

   ii. a CDR2 comprising the amino acid sequence of SEQ ID NO: 12 or has 2 or 1 amino acid difference(s) with SEQ ID NO: 12; and

   iii. a CDR3 comprising the amino acid sequence of SEQ ID NO: 15 or has 2 or 1 amino acid difference(s) with SEQ ID NO: 15.

9. The polypeptide or composition according to any of claims 7 or 8, wherein the ISVD binding to human serum albumin comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 9, a CDR2 comprising the amino acid sequence of SEQ ID NO: 12 and a CDR3 comprising the amino acid sequence of SEQ ID NO: 15.

10. The polypeptide or composition according to any of claims 7 to 9, wherein the amino acid sequence of said ISVD binding to human serum albumin comprises a sequence identity of more than 90% with SEQ ID NO: 5.

11. The polypeptide or composition according to any of claims 7 to 10, wherein said ISVD binding to human serum albumin comprises the amino acid sequence of SEQ ID NO: 5.

12. The polypeptide or composition according to any of claims 1 to 11, wherein the amino acid sequence of the polypeptide comprises a sequence identity of more than 90% with SEQ ID NO: 1.

13. The polypeptide or composition according to any of claims 1 to 12, wherein the polypeptide comprises or consists of the amino acid sequence of SEQ ID NO: 1.

14. A nucleic acid comprising a nucleotide sequence that encodes a polypeptide according to any of claims 1 to 13.

15. A host or host cell comprising a nucleic acid according to claim 14.

16. A method for producing a polypeptide according to any of claims 1 to 13, said method at least comprising the steps of:
    a. expressing, in a suitable host cell or host organism or in another suitable expression system, a nucleic acid according to claim 14; optionally followed by:
    b. isolating and/or purifying the polypeptide according to any of claims 1 to 13.

17. A composition comprising at least one polypeptide according to any of claims 1 to 13, or a nucleic acid according to claim 14.

18. The composition according to claim 17, which is a pharmaceutical composition which further comprises at least one pharmaceutically acceptable carrier, diluent or excipient and/or adjuvant, and optionally comprises one or more further pharmaceutically active polypeptides and/or compounds.

19. The polypeptide according to any of claims 1 to 13 or the composition according to any of claims 17 or 18 for use as a medicament.

20. The polypeptide according to any of claims 1 to 13 or the composition according to any of claims 17 or 18 for use in the treatment of an autoimmune or an inflammatory disease.

21. The polypeptide or composition for use according to claim 20, wherein the autoimmune or inflammatory disease is selected from rheumatoid arthritis, inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, psoriasis, Hidradenitis suppurativa, and graft-versus-host disease.

22. A method of treating an autoimmune disease or an inflammatory disease, wherein said method comprises administering, to a subject in need thereof, a pharmaceutically active amount of a polypeptide according to any of claims 1 to 13 or a composition according to any of claims 17 or 18.

23. The method according to claim 22, wherein the autoimmune disease or inflammatory disease is selected from rheumatoid arthritis, inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, psoriasis, Hidradenitis suppurativa, and graft-versus-host disease.

24. Use of a polypeptide according to any of claims 1 to 13 or a composition according to any of claims 17 or 18, in the preparation of a pharmaceutical composition for treating an autoimmune disease or an inflammatory disease.

25. Use of the polypeptide or composition according to claim 24, wherein the autoimmune disease or inflammatory disease is selected from rheumatoid arthritis, inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, psoriasis, Hidradenitis suppurativa, graft-versus-host disease.